Floatz logo

PF-08046044

Lymphoma, Large-Cell, Anaplastic

Seagen, a wholly owned subsidiary of PfizerPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Lymphoma, Large-Cell, Anaplastic cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Seagen Inc.
Phase 4BBB
Crizotinib
Pfizer
Phase 4BBB
Inno-206
City of Hope Medical Center
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Brentuximab Vedotin
Seagen Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

PF-08046044 is also rated in:

Hodgkins lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CC
Indicative ·
43 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →